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Abstract: It is well-established that tumour necrosis factor (TNF)--antagonist regimens are advisable for the control of 
moderate to severe psoriasis; however the application of these agents is associated with increased risk of TB reactivation. 
Screening for latent tuberculosis infection (LTBI) is indispensable prior to treatment inception in order to diminish the 
risk of active TB. Although tuberculin skin test (TST) still represents a useful tool for LTBI detection, it is difficult to be 
performed and read in patients with extensive psoriatic lesions. In this paper, we report the case of a 65-year-old male 
with severe psoriasis, who was evaluated by an interferon-gamma release assay (IGRA) for LTBI diagnosis prior to anti-
TNF- therapy. Furthermore, the physiological aspects of interferon-gamma release assays are discussed emphasizing the 
value of these novel immunodiagnostic tests (IGRAs) for presumable LTBI in all patients with extensive skin disorders. 
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INTRODUCTION 
  Epidemiological evidence predicts that about one-third of 
the earth’s population is presently infected by 
Mycobacterium tuberculosis, including a considerable 
fraction of individuals with latent tuberculosis infection 
(LTBI) [1]. Psoriasis with a worldwide prevalence of about 
1% is a common chronic inflammatory skin disease with 
considerable impact on the quality of life of the affected 
individuals. Different systemic therapies, including TNF--
antagonist regimens, are now available for the control of 
moderate to severe psoriasis; however the application of 
most of these modalities is connected with increased risk of 
TB reactivation [2]. Therefore, pre-screening of these 
patients for LTBI is mandatory prior to treatment initiation 
in order to minimize the risk of treatment-induced TB 
activation. 
  However, the diagnosis of LTBI is subjected to 
considerable clinical uncertainty. Tuberculin skin testing 
(TST) based guidelines are still widely applied to evaluate 
patients for LTBI. TST has been extensively used for nearly 
100 years in clinical practice, yet it has several drawbacks: 
low specificity in patients with previous bacillus Calmette-
Guérin (BCG) vaccination or exposure to non-tuberculous 
mycobacterial species as well as low sensitivity among 
patients with impaired immune function. Moreover in some 
patients, like those with severe psoriasis, extensive skin 
morbidity barely leaves healthy skin islands for TST 
measurement [3,4]. Although this is a rather uncommon 
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event, it may prove a decisive hurdle for the proper 
evaluation of TST by the Mantoux method. We hereby 
present an alternative to rule out LTBI. 
CASE REPORT 
  A 65-year-old male with late-onset psoriasis presented 
with severe sub-erythrodermic disease covering almost 
completely his integument (Psoriasis Area and Severity 
Index, PASI=29.8). During the last 5 years he was serially 
treated with topical corticosteroids and acitretin, 
cyclosporine and efalizumab with only partial improvement. 
Ongoing deterioration of his condition insisted treatment 
with infliximab. The patient had no history of M. 
tuberculosis exposure or other known risk factors for 
tuberculosis. A chest radiograph was carried out with normal 
findings. QuantiFERON-TB Gold in-Tube (QFT-GIT) assay 
was performed in our patient for the pretreatment assessment 
of his M. tuberculosis infection status showing negative 
results. QFT-GIT was preferred instead of the standard TST-
based methodology because of his extensive skin 
involvement. Inliximab was started as indicated with 
substantial improvement of his psoriasis (PASI 8.3 and 1.2 
after 2 and 4 months of treatment respectively). No signs of 
systemic infections, including tuberculosis were recorded 
during the one-year follow-up period under infliximab 
treatment. 
DISCUSSION 
 Recently  in vitro immunodiagnostic assays have been 
developed in order to surmount some of the TST limitations. 
These assays measure interferon (IFN)- production in whole 
blood or production of peripheral blood mononuclear cells 
(PBMC) in response to antigens (early secreted antigen; 60    The Open Respiratory Medicine Journal, 2011, Volume 5  Katsenos et al. 
ESAT-6, culture filtrate protein; CFP-10) that are specific 
for M. tuberculosis and absent from BCG and most 
environmental mycobacteria. Herein, these assays will be 
referred to as IFN-gamma release assays (IGRA). The two 
commercially available tests are the T SPOT-TB assay, an 
enzyme-linked immunosorbent spot or ELISPOT test that 
uses peripheral blood mononuclear cells, and the 
QuantiFERON-TB Gold (QFT-G), an enzyme-linked 
immunosorbent assay (ELISA) that uses whole blood [5]. 
Recently, a novel in-tube format of QFT-G (QFT-GIT) has 
been marketed, which, apart from peptides of ESAT-6 and 
CFP-10, contains an additional peptide of the M. 
tuberculosis-specific antigen TB7.7 [6]. This newest version 
of QFT-G was employed in the present case. 
  Meanwhile, accumulating evidence suggests that 
commercially available interferon-gamma release assays 
(IGRAs) have higher specificity than the TST in detecting 
LTBI, particularly in BCG-vaccinated patients as well as 
greater sensitivity to detect infection after a known M. 
tuberculosis exposure in settings with low tuberculosis 
incidence [5,7]. IGRAs may be better at detecting recent 
rather than remote infection. It has been hypothesized that 
short incubation interferon-gamma release assays (both 
commercial assays use 16-24h incubation) detect responses 
of activated effector T cells that have recently encountered 
antigens in vivo and can therefore rapidly release interferon- 
when stimulated in vitro. On the contrary, long-lived central 
memory T cells that may persist even after clearance of the 
organism (previously treated tuberculosis) may be less likely 
to release interferon- during short incubation period [8]. 
Moreover, IGRAs seem to be superior to TST to detect LTBI 
in immunosuppressed patients [9]. 
  Here on the occasion of such a patient with psoriatic 
erythrodermia, who had to be evaluated for LTBI prior to the 
initiation of anti-tumour necrosis factor-alpha (TNF-) 
therapy we would like to draw attention to the decisive 
advantage of IGRAs over the TST-based methodology in the 
evaluation of patients with extensive skin disease. 
  The assessment of the value of IGRAs as diagnostic tools 
in detecting LTBI in patients that are candidates for 
receiving anti-TNF- therapy is currently under investigation 
[10]. Newly we showed that adherence to TST-based TB 
evaluation overestimates the risk of LTBI in adult patients 
with overt plaque psoriasis [4]. The present report highlights 
an additional hurdle in the proper evaluation of TST in the 
subset of dermatological patients and is a reminder that 
IGRAs should be considered as first-line diagnostic 
procedure for putative LTBI in all patients with extensive 
skin morbidity, like psoriatic erythrodermia, severe atopic 
eczema or Sezary syndrome, where the application of TST is 
unfeasible. 
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